Community Trials

Join active peptide trials and contribute to community science.

Track your protocols, compare results with thousands of users, and help advance peptide research. All participation is voluntary and anonymous.

💡 How Community Trials Work

Voluntary participation: Join any trial that matches your current protocol
Track your data: Log doses, results, and side effects as usual
Anonymous contribution: Your data helps others while staying completely private
Compare results: See how your outcomes compare to other participants
Advance science: Contribute to the world's largest peptide effectiveness database
Opt out anytime: You can leave any trial without penalty

Active Trials (Recruiting Now)

🔥 RECRUITING NOW

BPC-157 for Tendon Injuries

Started: January 2024 | Duration: 8 weeks | Status: Active

247 Active Participants

8 Weeks Duration

73% Improvement Rate

4.2 Avg Pain Reduction

Study Goals:

Determine the optimal BPC-157 dosing protocol for tendon healing. Compare different doses (250mcg vs 500mcg), frequencies (daily vs twice daily), and injection sites (local vs systemic).

What We're Measuring:

Pain levels (0-10 scale) daily
Range of motion and mobility
Time to return to activity
Side effects and tolerability
Ultrasound or MRI changes (if available)

Current Findings:

500mcg 2x daily shows 73% improvement vs 58% for 250mcg daily
Local injection near injury site shows 1.4x faster healing than systemic
Average pain reduction: 4.2 points on 0-10 scale by week 4
Side effects: Minimal (3% report mild injection site irritation)

✓ Eligibility Requirements:

Current tendon injury (tennis elbow, Achilles, rotator cuff, etc.)
Planning to use BPC-157 for at least 8 weeks
Willing to log daily pain levels and weekly mobility assessments
No other healing peptides during trial period

Join This Trial → View Full Results →

🔥 RECRUITING NOW

Semaglutide/Tirzepatide Weight Loss Optimization

Started: October 2023 | Duration: 68 weeks | Status: Active

1,834 Active Participants

68 Weeks Duration

16.8% Avg Weight Loss

82% Completion Rate

Study Goals:

Compare different titration schedules, identify factors that predict success, and determine optimal strategies for minimizing side effects while maximizing weight loss.

What We're Measuring:

Weekly weight and body composition
Side effects (nausea, vomiting, constipation)
Adherence and dose escalation timing
Lifestyle factors (diet, exercise, sleep)
Lab values (if available): glucose, HbA1c, lipids

Current Findings:

Average weight loss: 16.8% at 68 weeks (Semaglutide 15.2%, Tirzepatide 19.1%)
Nausea peaks at week 2-3, resolves by week 8 in 82% of users
Evening injection reduces nausea by 34% compared to morning
Slower titration (5-week intervals) shows better adherence than standard 4-week
Protein intake >80g/day associated with 23% better muscle preservation

✓ Eligibility Requirements:

Starting Semaglutide or Tirzepatide for weight loss
BMI ≥27 with comorbidities or BMI ≥30
Willing to log weekly weight and side effects
Commit to at least 68 weeks of tracking

Join This Trial → View Full Results →

🔥 RECRUITING NOW

CJC-1295 + Ipamorelin for Muscle Growth

Started: February 2024 | Duration: 12 weeks | Status: Active

412 Active Participants

12 Weeks Duration

3.2kg Avg Muscle Gain

1.8kg Avg Fat Loss

Study Goals:

Measure muscle gain and body composition changes with CJC-1295 + Ipamorelin. Compare different dosing frequencies, timing protocols, and stacking strategies.

What We're Measuring:

Body weight and composition (DEXA or bioimpedance)
Strength gains (1RM or estimated)
Sleep quality scores
Recovery metrics
Side effects and tolerability

Current Findings:

Average muscle gain: 3.2kg lean mass over 12 weeks
Average fat loss: 1.8kg simultaneously
Before bed dosing shows 2.1x better sleep quality vs morning
5-on-2-off schedule shows similar results to daily with better sustainability
Side effects: Minimal (water retention in 12%, transient)

✓ Eligibility Requirements:

Starting CJC-1295 + Ipamorelin stack
Consistent resistance training (3+ days/week)
Willing to track body composition and strength
No other growth hormone peptides during trial

Join This Trial → View Full Results →

Completed Trials

✓ COMPLETED

PT-141 for Female Sexual Dysfunction

Completed: March 2024 | Duration: 12 weeks | Participants: 342

Key Findings:

78% reported improvement in sexual desire and arousal
Optimal dose: 1.0-1.5mg (lower than FDA-approved 1.75mg)
Nausea reduced 47% with anti-nausea medication 30 min before
Evening injection allowed sleeping through worst nausea
Effects lasted 12-18 hours on average

View Full Results →

Ready to Contribute to Peptide Science?

Join thousands of users tracking their protocols and advancing our understanding of peptides

Create Free Account →